Quanterix/$QTRX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Quanterix
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Ticker
$QTRX
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
471
ISIN
US74766Q1013
Website
Quanterix Metrics
BasicAdvanced
$271M
-
-$1.24
1.05
-
Price and volume
Market cap
$271M
Beta
1.05
52-week high
$16.74
52-week low
$4.05
Average daily volume
777K
Financial strength
Current ratio
8.293
Quick ratio
7.306
Long term debt to equity
9.946
Total debt to equity
11.507
Profitability
EBITDA (TTM)
-53.677
Gross margin (TTM)
59.67%
Net profit margin (TTM)
-35.28%
Operating margin (TTM)
-44.81%
Effective tax rate (TTM)
5.26%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-9.38%
Return on equity (TTM)
-14.51%
Valuation
Price to revenue (TTM)
1.981
Price to book
0.86
Price to tangible book (TTM)
0.92
Price to free cash flow (TTM)
-8.145
Free cash flow yield (TTM)
-12.28%
Free cash flow per share (TTM)
-85.70%
Growth
Revenue change (TTM)
7.71%
Earnings per share change (TTM)
45.69%
3-year revenue growth (CAGR)
6.32%
3-year earnings per share growth (CAGR)
-11.55%
What the Analysts think about Quanterix
Analyst ratings (Buy, Hold, Sell) for Quanterix stock.
Quanterix Financial Performance
Revenues and expenses
Quanterix Earnings Performance
Company profitability
Quanterix News
AllArticlesVideos
Quanterix Expands Reach with IVD and Large Reference Labs
Business Wire·2 weeks ago
Quanterix to Present at Goldman Sachs Global Healthcare Conference
Business Wire·4 weeks ago
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Quanterix stock?
Quanterix (QTRX) has a market cap of $271M as of July 04, 2025.
What is the P/E ratio for Quanterix stock?
The price to earnings (P/E) ratio for Quanterix (QTRX) stock is 0 as of July 04, 2025.
Does Quanterix stock pay dividends?
No, Quanterix (QTRX) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Quanterix dividend payment date?
Quanterix (QTRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Quanterix?
Quanterix (QTRX) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.